Loading…
Bluesail Medical Co., Ltd. announced its intention to acquire 100% equity interest in New Valve Technology (NVT), a Swiss developer and manufacturer of transcatheter interventional heart valves, with a total consideration of RMB 1.39 billion for the acquisition and subsequent capital injection. The acquisition will expand Bluesail's portfolio in cardiovascular high-value consumables.